These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 11123370

  • 1. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 2. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 3. 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.
    Higelin J, Py-Lang G, Paternoster C, Ellis GJ, Patel A, Dautzenberg FM.
    Neuropharmacology; 2001 May 15; 40(1):114-22. PubMed ID: 11077077
    [Abstract] [Full Text] [Related]

  • 4. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb 15; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

  • 5. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep 15; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 6. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.
    Dautzenberg FM, Wille S, Lohmann R, Spiess J.
    Proc Natl Acad Sci U S A; 1998 Apr 28; 95(9):4941-6. PubMed ID: 9560207
    [Abstract] [Full Text] [Related]

  • 7. Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart.
    Dautzenberg FM, Higelin J, Brauns O, Butscha B, Hauger RL.
    Mol Pharmacol; 2002 May 28; 61(5):1132-9. PubMed ID: 11961131
    [Abstract] [Full Text] [Related]

  • 8. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
    Lawrence AJ, Krstew EV, Dautzenberg FM, Rühmann A.
    Br J Pharmacol; 2002 Jul 28; 136(6):896-904. PubMed ID: 12110614
    [Abstract] [Full Text] [Related]

  • 9. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 10. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 11. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 06; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 12. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
    Okada R, Miller MF, Yamamoto K, De Groef B, Denver RJ, Kikuyama S.
    Gen Comp Endocrinol; 2007 Feb 06; 150(3):437-44. PubMed ID: 17188689
    [Abstract] [Full Text] [Related]

  • 13. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.
    Dautzenberg FM, Huber G, Higelin J, Py-Lang G, Kilpatrick GJ.
    Neuropharmacology; 2000 Jun 08; 39(8):1368-76. PubMed ID: 10818253
    [Abstract] [Full Text] [Related]

  • 14. Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding.
    Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM.
    J Neurochem; 1999 Jan 08; 72(1):388-95. PubMed ID: 9886092
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R.
    J Pharmacol Exp Ther; 2003 Apr 08; 305(1):57-69. PubMed ID: 12649353
    [Abstract] [Full Text] [Related]

  • 16. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
    Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O, Bienert M, Berger H.
    Br J Pharmacol; 2007 Jul 08; 151(6):851-9. PubMed ID: 17533422
    [Abstract] [Full Text] [Related]

  • 17. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, Gravanis A, Liapakis G.
    Mol Pharmacol; 2009 Apr 08; 75(4):793-800. PubMed ID: 19124613
    [Abstract] [Full Text] [Related]

  • 18. Ligand requirements of the human corticotropin-releasing factor-binding protein.
    Sutton SW, Behan DP, Lahrichi SL, Kaiser R, Corrigan A, Lowry P, Potter E, Perrin MH, Rivier J, Vale WW.
    Endocrinology; 1995 Mar 08; 136(3):1097-102. PubMed ID: 7867564
    [Abstract] [Full Text] [Related]

  • 19. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
    Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL.
    J Neurochem; 1999 Aug 08; 73(2):821-9. PubMed ID: 10428081
    [Abstract] [Full Text] [Related]

  • 20. Corticotropin-releasing factor receptors induce calcium mobilization through cross-talk with Gq-coupled receptors.
    Gutknecht E, Vauquelin G, Dautzenberg FM.
    Eur J Pharmacol; 2010 Sep 10; 642(1-3):1-9. PubMed ID: 20594969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.